Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LUZ19
- Development stage
- Preclinical
- Lead developer
- KU Leuven
- Administration
- Inhalation, Intravenous, Oral, Topical
01
Overview
LUZ19 is a lytic bacteriophage (specifically a podovirus belonging to the family *Autographivirinae*) that targets *Pseudomonas aeruginosa*. It is being investigated as a therapeutic agent (phage therapy) for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Pseudomonas aeruginosa* infections, including those in patients with cystic fibrosis or burn wounds. LUZ19 is a pili-targeted phage that adsorbs to the host cell and completes its lytic cycle within approximately 25 minutes. It has been evaluated in preclinical models, such as the Hollow Fiber Infection Model (HFIM), both as monotherapy and in combination with other phages (e.g., PYO2, E215) or antibiotics (e.g., aztreonam) to overcome resistance and enhance bactericidal activity.
- Other names
- Pseudomonas phage LUZ19bacteriophage LUZ19phage LUZ19
02
Targets
PilA (Type IV pilus protein PilA)
Beyond the preview
Go deeper on LUZ19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUZ19.